Publications by authors named "Isabelle Fleury"

Claim this Profile
M
Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study.
Anthea Peters, Grzegorz S Nowakowski, Rosy Dabas, Theresa Amoloja, Zhenyi Xue, Isabelle Fleury

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Richard T Maziarz, Michael R Bishop, Constantine S Tam, Peter Borchmann, Nina Worel, Isabelle Fleury

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Structured Peer Support Pathways for Patients Undergoing Cellular Therapies: Insights from a Participatory Study.
Karine Bilodeau, Pegah Torabi, Ludovic Tamaro, Sandie Oberoi, Deborah Pascale, Isabelle Fleury

Curr Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter Transformation.
Mathias Castonguay, Marie-France Gagnon, Alexandre Le Nguyen, Rafik Terra, Sarah-Jeanne Pilon, Isabelle Fleury

Curr Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.
David MacDonald, Robert Puckrin, Pamela Skrabek, Selay Lam, Jai Jayakar, Isabelle Fleury

Curr Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.
Mathias Castonguay, Jean Roy, Jean-Sébastien Claveau, Sylvie Lachance, Jean-Sébastien Delisle, Isabelle Fleury

Curr Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor, Isabelle Fleury

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report.
Mathias Castonguay, Léa Bernard, Marylène Corriveau, Anik Castonguay, Geneviève Quenneville, Isabelle Fleury

Transfusion· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.
Eva Laverdure, Luigina Mollica, Imran Ahmad, Sandra Cohen, Silvy Lachance, Isabelle Fleury

Curr Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.
Isabelle Fleury, David MacDonald, Mona Shafey, Anna Christofides, Laurie H Sehn

Curr Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.
John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Isabelle Fleury

Br J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Douglas A Stewart, John Kuruvilla, David Lee, Jill J Dudebout, Neil Chua, Isabelle Fleury

Br J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, Isabelle Fleury

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, Isabelle Fleury

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Isabelle Fleury

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury

Ann Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.
Ulrich Jaeger, Nina Worel, Joseph P McGuirk, Peter A Riedell, Isabelle Fleury

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.
Jean Lachaine, Kimberly Guinan, Andrew Aw, Versha Banerji, Isabelle Fleury

Curr Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Sylvie Lachance, Alex Bourguignon, Josie-Anne Boisjoly, Philippe Bouchard, Imran Ahmad, Isabelle Fleury

Transplant Cell Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Ulrich Jaeger, Constantine S Tam, Peter Borchmann, Joseph P McGuirk, Marianne Johansen, Isabelle Fleury

Blood Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Informants for Mental Health Screening at the Preschool Level.
Stephanie A Moore, Erin Dowdy, Isabelle Fleury, Christine DiStefano, Fred W Greer

School Psych Rev· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis